Cross-Linked Nucleic Acid Affinity Reagents for Stable Analyte Binding

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Nucleic acid based affinity reagents face stability issues due to dynamic 3D structure changes, leading to partial unfolding or misfolding, which complicates their use and storage, and affect the efficacy of binding to target molecules.

Innovation Solution

A nucleic acid backbone with specific reaction moieties configured to form cross-links, maintaining a stable complex structure through covalent bonds, such as CuAAC or SpAAC, to ensure robust binding to target analytes.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of manufacture

If nucleic acid based affinity reagents are used, then cost-effectiveness and ease of production are improved, but structural stability and reliability deteriorate due to dynamic 3D structure changes

Engineering Contradiction:
Improveease of productionVSAvoidstructural stability
Core Design Contradiction:
Ease of manufactureVSReliability

Solution Approach 1:

The patent combines nucleic acid backbone with protein elements to create a hybrid affinity reagent structure. This composite approach integrates the cost-effectiveness and ease of production of nucleic acid-based reagents with the structural stability and reliability of protein-based reagents, resolving the contradiction between manufacturability and structural integrity

Inventive Principle:
Principle #40Composite materials

Solution Approach 2:

The patent modifies the physical and chemical parameters of the affinity reagent by incorporating stabilized 3D structures with controlled folding patterns. This allows the nucleic acid backbone to maintain its production advantages while achieving enhanced structural stability through parameter optimization of the molecular conformation

Inventive Principle:
Principle #35Parameter changes

2Reliability

If nucleic acid based affinity reagents are used, then affinity and specificity are improved, but ease of use deteriorates due to refolding requirements

Engineering Contradiction:
Improvebinding specificityVSAvoidease of use
Core Design Contradiction:
ReliabilityVSEase of operation

Solution Approach 1:

The patent implements preliminary stabilization of the 3D structure during the reagent design and production phase. By pre-establishing stable folded structures with defined binding conformations, the reagent arrives ready-to-use without requiring refolding operations, thus maintaining high binding specificity while improving ease of use

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The patent designs affinity reagents with inherently stable structures that maintain their binding capability throughout their operational lifespan without requiring refolding or reactivation. This disposable-ready design eliminates the need for complex handling procedures while preserving high affinity and specificity

Inventive Principle:
Principle #27Cheap short-living objects (Disposable)

3Ease of manufacture

If nucleic acid based affinity reagents are used, then cost-effectiveness is improved, but storage stability deteriorates due to partial unfolding

Engineering Contradiction:
Improvecost-effectivenessVSAvoidstorage stability
Core Design Contradiction:
Ease of manufactureVSDuration of action of stationary object

Solution Approach 1:

The patent creates a composite structure combining nucleic acid backbone with stabilizing elements that protect against unfolding during storage. This hybrid approach maintains the cost-effectiveness of nucleic acid production while adding structural features that extend storage stability and prevent partial unfolding

Inventive Principle:
Principle #40Composite materials

Solution Approach 2:

The patent incorporates structural features and protective elements during the design phase that cushion against environmental stresses during storage. This preemptive stabilization prevents partial unfolding and misfolding before they occur, extending the shelf life while maintaining cost-effectiveness

Inventive Principle:
Principle #11Beforehand cushioning (Prior cushioning)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The cross-linked nucleic acid backbone provides a stable and robust affinity reagent with high specificity and stability, enabling efficient binding to target analytes even under varying conditions.

Implementation Method 1

The nucleic acid backbone comprises at least one pair of reaction moieties for cross-linking the nucleic acid backbone

Methodology Applied
Scientific EffectCovalent bonding: Chemical Bonding

Implementation Method 2

The binding of the affinity reagent to the target analyte may comprise intermolecular forces such as hydrogen bonding, dipole-dipole interactions, ionic interactions, π-stacking, hydrophobic interaction, and van der Waals forces

Methodology Applied
Scientific EffectHydrogen bonding:

Implementation Method 3

The binding of the affinity reagent to the target analyte may comprise intermolecular forces such as hydrogen bonding, dipole-dipole interactions, ionic interactions, π-stacking, hydrophobic interaction, and van der Waals forces

Methodology Applied
Scientific EffectHydrophobic interaction:

Implementation Method 4

The binding of the affinity reagent to the target analyte may comprise intermolecular forces such as hydrogen bonding, dipole-dipole interactions, ionic interactions, π-stacking, hydrophobic interaction, and van der Waals forces

Methodology Applied
Scientific EffectVan der Waals forces: Van der Waals Force

Data Source

PatentEP4603584A1Affinity reagent, marker and method for analysing a biological sample
Publication Date: 2025.08.20 LEICA MICROSYSTEMS CMS GMBH
  • EP4603584A1 patent drawingFigure 1
  • EP4603584A1 patent drawingFigure 2
  • EP4603584A1 patent drawingFigure 3

AI summary

An affinity reagent (102, 102a, 102b) for analysing a biological sample is provided. The affinity reagent (102, 102a, 102b) comprises a nucleic acid backbone (200, 300, 402). The nucleic acid backbone (200, 300, 402) is configured to specifically bind to a target analyte (106) by its complex structure (400c). Further, the nucleic acid backbone (200, 300, 402) comprises at least one pair of reaction moieties (202, 204, 302, 304, 308, 310) for cross-linking the nucleic acid backbone (200, 300, 402). In further aspects, a marker and a method for analysing a biological sample are provided.